PLACE DE L'IRM DANS LA PATHOLOGIE DE LA MOELLE OSSEUSE DE LA HANCHE

GRENOBLE1-BU Médecine pharm. (385162101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

ELSI balbutie ! Vers une plateforme d'animation d'avatar signant

International audienc

Démonstrations d'Elsi, la signeuse virtuelle du LIMSI

International audienc

KAZOO: a sign language generation platform based on production rules

International audienceIn this paper, we describe KAZOO, a web application for sign language (SL) generation using a virtual signer. We first explain the motivation to this project, which is grounded on an SL-specific approach, i.e. designed solely from SL corpus analysis and modelling. Then, we present various projects we worked in the past few years, on linguistic modelling, and 3d animation. Our platform architecture integrates parts of this work and new pieces of software allowing control and linking of all these components. This is an on-going project, but the current version offer the possibility to automatically animate a virtual signer and synthesise the contents using an abstract representation, our linguistic model AZee, providing a means of validating this model

VICTEAMS: a virtual environment to train medical team leaders to interact with virtual subordinates

International audienceHealth care delivery in military conflict, in peacekeeping missionsor in the aftermath of disaster, implies high stress environmentswith danger exposures, life-threatening events and high levels ofwork demand. Crisis and emergency risk communication remainsa real challenge. The rapid response of emergency medical teamshas an important role to play in preventing serious adverse events.During critical events, medical errors can be related to human or systemfactors, including ineffective team leadership, non-standardizedteam communication, a lack of global situation awareness, pooruse of resources and inappropriate triage and prioritization. TheVICTEAMS project aims at building a virtual environment for trainingrescue team leaders to non-technical skills. Depending on theleader abilities, the virtual characters playing the subordinates (e.g.nurses) reproduce a variety of behaviors like erroneous actions,followership attitudes or stress-based behaviors. A pedagogical directortailors the difficulty according to the dynamic profile of thelearner

Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?

International audienceBackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (<50 copies/mL) before 14 weeks of gestation (WG) while on rilpivirine, we compared the probability of viral rebound (≥50 copies/mL) during pregnancy between subjects continuing rilpivirine versus those switching to RFC.ResultsAmong 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was <50 copies/mL in 95.6% of women. Among 69 women with documented viral suppression before 14 WG, the risk of viral rebound was higher when switching to RFCs than when continuing rilpivirine (20.0% versus 0.0%, P = 0.046). Delivery outcomes were similar between groups (overall birth defects, 3.8/100 live births; pregnancy losses, 2.0%; preterm deliveries, 10.6%). No HIV transmission occurred.ConclusionsIn virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes

Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from FranceResearch in context

Summary: Background: No study has compared the virological and immunological status of young people with perinatally-acquired HIV infection (P-HIV) with that of people with HIV adulthood (A-HIV) having a similar duration of infection. Methods: 5 French cohorts of P-HIV and A-HIV patients with a known date of HIV-infection and receiving antiretroviral treatment (ART), were used to compare the following proportions of: virological failure (VF) defined as plasma HIV RNA ≥ 50 copies/mL, CD4 cell percentages and CD4:CD8 ratios, at the time of the most recent visit since 2012. The analysis was stratified on time since infection, and multivariate models were adjusted for demographics and treatment history. Findings: 310 P-HIV were compared to 1515 A-HIV (median current ages 20.9 [IQR:14.4–25.5] and 45.9 [IQR:37.9–53.5] respectively). VF at the time of the most recent evaluation was significantly higher among P-HIV (22.6%, 69/306) than A-HIV (3.3%, 50/1514); p ≤ 0.0001. The risk of VF was particularly high among the youngest children (2–5 years), adolescents (13–17 years) and young adults (18–24 years), compared to A-HIV with a similar duration of infection: adjusted Odds-Ratio (aOR) 7.0 [95% CI: 1.7; 30.0], 11.4 [4.2; 31.2] and 3.3 [1.0; 10.8] respectively. The level of CD4 cell percentages did not differ between P-HIV and A-HIV. P-HIV aged 6–12 and 13–17 were more likely than A-HIV to have a CD4:CD8 ratio ≥ 1: 84.1% vs. 58.8% (aOR = 3.5 [1.5; 8.3]), and 60.9% vs. 54.7% (aOR = 1.9 [0.9; 4.2]) respectively. Interpretation: P-HIV were at a higher risk of VF than A-HIV with a similar duration of infection, even after adjusting for treatment history, whereas they were not at a higher risk of immunological impairment. Exposure to viral replication among young patients living with HIV since birth or a very early age, probably because of lower adherence, could have an impact on health, raising major concerns about the selection of resistance mutations and the risk of HIV transmission. Funding: Inserm - ANRS MIE